Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. van Doorn · SciRah

Researcher profile · Semantic Scholar

L. van Doorn

Share profile

L. van Doorn — researcher profile on SciRah

h-index: 19
Works: 65
Citations: 1,019

Most-cited papers

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
F. Eskens, M. D. de Jonge, P. Bhargava, T. Isoe +7 more
2011Clinical Cancer Research106 citations Open access
Semantic Scholar
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance
J. Sprowl, L. van Doorn, S. Hu, L. V. van Gerven +5 more
2013Clinical pharmacology and therapy83 citations Open access
Semantic Scholar
Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
R. Verheijen, S. Bins, R. Mathijssen, M. Lolkema +6 more
2016Clinical Cancer Research73 citations Open access
Semantic Scholar
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
U. Banerji, L. van Doorn, D. Papadatos-Pastos, R. Kristeleit +10 more
2012Clinical Cancer Research72 citations Open access
Semantic Scholar
The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species specific insoluble metabolite formation
M. Lolkema, H. Bohets, H. Arkenau, A. Lampo +6 more
2015Clinical Cancer Research71 citations Open access
Semantic Scholar
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
F. Eskens, N. Steeghs, J. Verweij, J. Bloem +8 more
2009Journal of Clinical Oncology42 citations Open access
Semantic Scholar
Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
A. D. de Graan, W. Loos, L. Friberg, S. Baker +6 more
2012Clinical Cancer Research36 citations Open access
Semantic Scholar
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
S. Bins, Anne Lenting, S. el Bouazzaoui, L. van Doorn +4 more
2016Pharmacogenomics (London)34 citations
Semantic Scholar
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
F. A. Eskens, P. Tresca, D. Tosi, L. van Doorn +6 more
2014British Journal of Cancer34 citations Open access
Semantic Scholar
Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma
L. van Doorn, F. Eskens, T. Visser, A. W. van der Lugt +2 more
2011Thyroid32 citations
Semantic Scholar
Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands
F. Buisman, D. Grünhagen, M. Homs, C. Grootscholten +18 more
2019Annals of Surgical Oncology29 citations Open access
Semantic Scholar
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
M. Puglisi, L. Molife, M. D. de Jonge, K. Khan +8 more
2021Future Oncology27 citations Open access
Semantic Scholar
Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide
S. Bins, L. van Doorn, M. Phelps, A. Gibson +10 more
2017Clinical and Translational Science27 citations Open access
Semantic Scholar
The added value of H2 antagonists in premedication regimens during paclitaxel treatment
J. Cox, L. van Doorn, R. Malmberg, Esther Oomen-de Hoop +6 more
2021British Journal of Cancer24 citations Open access
Semantic Scholar
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
M. de With, L. van Doorn, E. Kloet, Anne van Veggel +7 more
2023Clinical Pharmacokinetics23 citations Open access
Semantic Scholar
A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.
M. Puglisi, L. van Doorn, M. Blanco-Codesido, M. D. de Jonge +9 more
2011Journal of Clinical Oncology23 citations
Semantic Scholar
An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors.
F. A. Eskens, A. Planting, L. van Doorn, Toshiyuki Isoe +5 more
2006Journal of Clinical Oncology22 citations
Semantic Scholar
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
M. de With, L. van Doorn, D. Maasland, Tessa A. Mulder +7 more
2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie19 citations Open access
Semantic Scholar
Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
D. V. van Dorst, L. van Doorn, K. M. Mirabito Colafella, O. Manintveld +4 more
2021Clinical science19 citations Open access
Semantic Scholar
Capecitabine and the Risk of Fingerprint Loss
L. van Doorn, Sebastiaan Veelenturf, Lisette Binkhorst, S. Bins +1 more
2017JAMA Oncology19 citations Open access
Semantic Scholar
Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage
K. M. Mirabito Colafella, D. V. van Dorst, R. Neuman, L. van Doorn +13 more
2022Clinical science16 citations Open access
Semantic Scholar
Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial
L. van Doorn, N. Heersche, Femke M. de Man, P. de Bruijn +6 more
2021Clinical pharmacology and therapy15 citations Open access
Semantic Scholar
Chemotherapy aNd chemoradiotherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial
C. J. van der Zijden, B. Eyck, A. van der Gaast, L. van Doorn +5 more
2022Contemporary Clinical Trials Communications14 citations Open access
Semantic Scholar
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma
C. Beukhof, L. van Doorn, Theo J. Visser, S. Bins +8 more
2017Journal of Clinical Endocrinology and Metabolism14 citations
Semantic Scholar
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
K. Hussaarts, L. van Doorn, K. Eechoute, J. Damman +13 more
2020Pharmaceutics13 citations Open access
Semantic Scholar
Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study
C. J. van der Zijden, Anna Bouwman, B. Mostert, J. Nuyttens +7 more
2024Diseases of the esophagus12 citations Open access
Semantic Scholar
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
N. A. D. Guchelaar, R. A. G. van Eerden, S. Groenland, L. van Doorn +7 more
2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie10 citations Open access
Semantic Scholar
Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients
Femke M. de Man, R. A. G. van Eerden, Esther Oomen-de Hoop, J. N. Veraart +4 more
2019Cancers10 citations Open access
Semantic Scholar
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
C. Oldenhuis, W. Loos, B. Esteves, L. van Doorn +6 more
2015Clinical colorectal cancer10 citations Open access
Semantic Scholar
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
K. Hussaarts, L. van Doorn, S. Bins, D. Sprengers +5 more
2021Pharmaceuticals9 citations Open access
Semantic Scholar
A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.
F. A. Eskens, C. Oldenhuis, P. Bhargava, W. Loos +6 more
2011Journal of Clinical Oncology9 citations
Semantic Scholar
Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
R. A. G. van Eerden, L. van Doorn, Femke M. de Man, N. Heersche +11 more
2021Frontiers in Pharmacology7 citations Open access
Semantic Scholar
Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.
P. Tresca, D. Tosi, L. van Doorn, H. Fontaine +5 more
20107 citations
Semantic Scholar
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension
L. van Doorn, W. Visser, D. V. van Dorst, K. M. Mirabito Colafella +11 more
2022British Journal of Cancer6 citations Open access
Semantic Scholar
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients
L. van Doorn, Marie-Rose B. S. Crombag, H. N. Rier, J. V. van Vugt +5 more
2021Pharmaceuticals6 citations Open access
Semantic Scholar
Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors.
H. Gelderblom, J. Verweij, N. Steeghs, A. R. van Erkel +6 more
2006Journal of Clinical Oncology6 citations
Semantic Scholar
Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial
M. Zietse, Luuk C. Aalders, Leontine E A M M Spierings, N. de Rouw +8 more
2025BMJ Open5 citations
Semantic Scholar
Machine Learning–Based Prediction of Clinical Outcomes in Patients With Cancer Receiving Systemic Treatment Using Step Count Data Measured With Smartphones
Calvin G. Brouwer, Branca M. Bartelet, J. A. Douma, L. van Doorn +3 more
2025JCO Clinical Cancer Informatics5 citations Open access
Semantic Scholar
Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases.
N. Ijzerman, W. Filipe, P. de Bruijn, F. Buisman +13 more
2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie5 citations Open access
Semantic Scholar
Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy.
J. Versmissen, L. van Doorn, K. M. Mirabito Colafella, R. Mathijssen +1 more
2018Journal of Hypertension5 citations
Semantic Scholar
486PINDIVIDUALIZED PHARMACOKINETICALLY-GUIDED DOSING OF PAZOPANIB: A FEASIBILITY STUDY IN CANCER PATIENTS.
R. Verheijen, S. Bins, C. G. Gadellaa-van Hooijdonk, R. Mathijssen +7 more
2014Annals of Oncology4 citations Open access
Semantic Scholar
Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.
F. Eskens, C. Oldenhuis, W. Loos, B. Esteves +7 more
20123 citations
Semantic Scholar
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.
U. Banerji, L. van Doorn, D. Papadatos-Pastos, P. Debnam +5 more
20103 citations
Semantic Scholar
Adjuvant hepatic arterial infusion pump chemotherapy with floxuridine for patients with resectable colorectal liver metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial.
L. Outmani, F. Buisman, W. Filipe, K. Bolhuis +16 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study
N. A. D. Guchelaar, S. Buck, L. van Doorn, K. Hussaarts +12 more
2024Clinical Pharmacokinetics2 citations Open access
Semantic Scholar
Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
L. van Doorn, Mandy M. van Rosmalen, W. M. van der Deure, Esther Oomen-de Hoop +10 more
2021Cancers2 citations Open access
Semantic Scholar
72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors
H. Gelderblom, J. Verweij, N. Steeghs, E. D. de Koning +6 more
20062 citations
Semantic Scholar
Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study
Ruben Malmberg, L. van Doorn, J. Cox, Alaa Daloul +6 more
2024JCO Oncology Practice1 citations Open access
Semantic Scholar
Chemotherapy and chemoradiotherapy for adenocarcinoma of the esophagus and junction with oligometastases: Results of the TNT-OES-1 trial.
C. J. van der Zijden, T. Huizer, B. Eyck, A. van der Gaast +9 more
2024Journal of Clinical Oncology1 citations
Semantic Scholar
305 Influencing sorafenib disposition by blocking hepatocellular sorafenib-glucuronide uptake with rifampin in mice and humans
S. Bins, L. van Doorn, A. Gibson, Shui-Ying Hu +8 more
20151 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Mathijssen×18
Invite
R. Mathijssen — researcher profile on SciRah
F. Eskens×15
Invite
F. Eskens — researcher profile on SciRah
S. Bins×15
Invite
S. Bins — researcher profile on SciRah
Esther Oomen-de Hoop×12
Invite
Esther Oomen-de Hoop — researcher profile on SciRah

×10

Invite

P. de Bruijn — researcher profile on SciRah

Invite

J. Verweij — researcher profile on SciRah

Invite

S. Koolen — researcher profile on SciRah

F. A. Eskens×6

Invite

F. A. Eskens — researcher profile on SciRah

A. van der Gaast×6

Invite

A. van der Gaast — researcher profile on SciRah

R. V. van Leeuwen×6

Invite

R. V. van Leeuwen — researcher profile on SciRah

M. D. de Jonge×5

Invite

M. D. de Jonge — researcher profile on SciRah

Invite

B. Mostert — researcher profile on SciRah